Predict your next investment

Human Longevity company logo
Corporation
HEALTHCARE | Biotechnology
humanlongevity.com

See what CB Insights has to offer

Stage

Reverse Merger

Total Raised

$330M

Investors Count

7

Deal Terms

3

Portfolio Exits

3

Investments

8

Human Longevity Funding, Human Longevity Valuation & Human Longevity Revenue

4 Fundings

Human Longevity's latest funding round was a Series C for $30M on July 1, 2019.

Human Longevity's valuation in March 2014 was $210.07M.

Human Longevity's latest post-money valuation is from July 2019.

Sign up for a free 30-day trial to see Human Longevity's valuations in July 2019 and more.

Date

Round

Amount

Investors

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Revenue

Sources

7/1/2019

Series C

$30M

Emerging Technology Partners, and Undisclosed Investors

$99M

$0.00B

((9.99x))

FY 1234

6

4/4/2016

Series B

$99M

$0.00B

((9.99x))

FY 1234

10

3/5/2014

Series A

$99M

$210.07M

$0.00B

((9.99x))

FY 1234

10

Other Investors

$99M

$0.00B

((9.99x))

FY 1234

10

Date

7/1/2019

4/4/2016

3/5/2014

Round

Series C

Series B

Series A

Other Investors

Amount

$30M

$99M

$99M

$99M

Investors

Emerging Technology Partners, and Undisclosed Investors

Valuation

$99M

$210.07M

Revenue

$0.00B

((9.99x))

FY 1234

$0.00B

((9.99x))

FY 1234

$0.00B

((9.99x))

FY 1234

$0.00B

((9.99x))

FY 1234

Sources

6

10

10

10

Human Longevity Deal Terms

3 Deal Terms

Human Longevity's deal structure is available for 3 funding rounds, including their Series C from July 01, 2019.

Round

Series C

Series B

Series A

Funding Date

$99M

$99M

Pre-Money Valuation

$99M

$99M

Post-Money Valuation

$99M

$99M

Amount Raised

$99M

$99M

Shares Authorized

Issuance Price

$99M

Dividend Rate

Liquidation Preferences

$99M

Liquidation Price

Participation

Conversion Price

Anti Dilution

$99M

General Voting

$99M

$99M

Board Voting

$99M

$99M

Par Value

Round

Funding Date

Pre-Money Valuation

Post-Money Valuation

Amount Raised

Shares Authorized

Issuance Price

Dividend Rate

Liquidation Preferences

Liquidation Price

Participation

Conversion Price

Anti Dilution

General Voting

Board Voting

Par Value

Series C

$99M

$99M

$99M

$99M

$99M

$99M

Series B

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

Series A

Human Longevity Investors

7 Investors

Human Longevity has 7 investors. Emerging Technology Partners invested in Human Longevity's Series C funding round.

First funding

Last Funding

Investor

Rounds

Board Seats

Type

Location

7/1/2019

7/1/2019

1
Series C

Venture Capital

California

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

Venture Capital

California

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

Corporation

California

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

Corporate Venture

California

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

Venture Capital

California

First funding

7/1/2019

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Last Funding

7/1/2019

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Investor

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Rounds

1
Series C

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Board Seats

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Type

Venture Capital

Venture Capital

Corporation

Corporate Venture

Venture Capital

Location

California

California

California

California

California

Human Longevity Acquisitions

4 Acquisitions

Human Longevity acquired 4 companies. Their latest acquisition was DoctorsForMe.AI on January 15, 2020.

Date

Investment Stage

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Total Funding

Note

Sources

1/15/2020

Series A

$1M

Acquired

1

1/28/2016

Subscribe to see more

$99M

Subscribe to see more

10

1/28/2016

Subscribe to see more

$99M

Subscribe to see more

10

11/30/2015

Subscribe to see more

$99M

Subscribe to see more

10

Date

1/15/2020

1/28/2016

1/28/2016

11/30/2015

Investment Stage

Series A

Companies

Subscribe to see more

Subscribe to see more

Subscribe to see more

Valuation

Total Funding

$1M

$99M

$99M

$99M

Note

Acquired

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

1

10

10

10

Human Longevity Investments

8 Investments

Human Longevity has made 8 investments. Their latest investment was in Edifice Health as part of their Series B on April 4, 2021.

CBI Logo

Human Longevity Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

4/26/2021

Series B

Edifice Health

$12M

No

Ahren Innovation Capital, Alafi Capital, Ataraxia Capital Partners, Better Foods, Impact Venture Capital, Leaps by Bayer, M4Capital, Paladin Capital Group, Shanda Group, Summer Venture Capital, Taisho Pharmaceutical, The Carlyle Group, The Longevity Fund, and Vertical Venture Partners

3

12/16/2020

Series B

Subscribe to see more

$99M

Subscribe to see more

10

9/22/2020

Series A

Subscribe to see more

$99M

Subscribe to see more

10

7/14/2020

Series A

Subscribe to see more

$99M

Subscribe to see more

10

6/29/2020

Series A

Subscribe to see more

$99M

Subscribe to see more

10

Date

4/26/2021

12/16/2020

9/22/2020

7/14/2020

6/29/2020

Round

Series B

Series B

Series A

Series A

Series A

Company

Edifice Health

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Amount

$12M

$99M

$99M

$99M

$99M

New?

No

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Co-Investors

Ahren Innovation Capital, Alafi Capital, Ataraxia Capital Partners, Better Foods, Impact Venture Capital, Leaps by Bayer, M4Capital, Paladin Capital Group, Shanda Group, Summer Venture Capital, Taisho Pharmaceutical, The Carlyle Group, The Longevity Fund, and Vertical Venture Partners

Sources

3

10

10

10

10

Human Longevity Portfolio Exits

3 Portfolio Exits

Human Longevity has 3 portfolio exits. Their latest portfolio exit was Celularity on July 16, 2021.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

7/16/2021

Reverse Merger

$991

6

00/00/0000

Subscribe to see more

Subscribe to see more

$991

Subscribe to see more

10

00/00/0000

Subscribe to see more

Subscribe to see more

$991

Subscribe to see more

10

Date

7/16/2021

00/00/0000

00/00/0000

Exit

Reverse Merger

Subscribe to see more

Subscribe to see more

Companies

Subscribe to see more

Subscribe to see more

Valuation

$991

$991

$991

Acquirer

Subscribe to see more

Subscribe to see more

Sources

6

10

10

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.